Pembrolizumab in combination with chemotherapy improves progression free survival for women with advanced or recurrent endometrial cancer
NRG Oncology Phase III clinical trial, NRG-GY018, evaluating pembrolizumab in combination with standard of care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression fre…
